STOCK TITAN

MacroGenics (MGNX) director granted options and RSUs, RSUs vest into shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MACROGENICS INC director Karen Jean Ferrante reported equity compensation transactions. On May 19, 2026, she received a stock option grant for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. She also received 3,750 restricted stock units (RSUs), each representing one future share of common stock, which vest one year after grant or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, increasing her direct common stock holdings to 14,750 shares.

Positive

  • None.

Negative

  • None.
Insider Ferrante Karen Jean
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 3,750 $0.00 --
Grant/Award Stock Option (right to buy) 22,000 $0.00 --
Exercise Restricted Stock Unit 3,750 $0.00 --
Exercise Common Stock 3,750 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 3,750 shares (Direct, null); Stock Option (right to buy) — 22,000 shares (Direct, null); Common Stock — 14,750 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Stock options granted 22,000 shares Option grant to director on May 19, 2026
Option exercise price $4.52 per share Exercise price of 22,000-share option grant
Option expiration May 19, 2036 Expiry date of stock option grant
RSUs granted 3,750 units New RSU award on May 19, 2026
RSUs vested and exercised 3,750 units RSUs vested and converted on May 18, 2026
Common shares after transaction 14,750 shares Direct MACROGENICS common stock held post-transaction
Derivative exercises 1 transaction, 3,750 shares Exercise of RSUs into common stock
Restricted Stock Unit financial
"The RSUs vested on May 18, 2026, which was one day prior..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option financial
"The option will vest and become exercisable in monthly, cumulative 1/12th increments..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vested financial
"The RSUs vested on May 18, 2026, which was one day prior..."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ferrante Karen Jean

(Last)(First)(Middle)
9704 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026M3,750A(1)14,750D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0(1)05/18/2026M3,750 (2) (2)Common Stock3,750$00D
Restricted Stock Unit$0(1)05/19/2026A3,750 (3) (3)Common Stock3,750$03,750D
Stock Option (right to buy)$4.5205/19/2026A22,000 (4)05/19/2036Common Stock22,000$022,000D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
2. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
3. The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
4. The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Remarks:
Beth A. Smith, Attorney-in-fact05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did MACROGENICS (MGNX) director Karen Ferrante receive?

Karen Ferrante received a stock option for 22,000 shares at an exercise price of $4.52 per share and 3,750 restricted stock units, each representing one future share of MACROGENICS common stock as part of her director compensation.

When do Karen Ferrante’s new MACROGENICS (MGNX) RSUs vest?

The newly granted 3,750 RSUs will vest one year after the May 19, 2026 grant date, or on the day prior to the next annual meeting, if that occurs earlier, according to the vesting terms disclosed for these restricted stock units.

What happened to Karen Ferrante’s previously granted MACROGENICS (MGNX) RSUs?

Previously granted RSUs totaling 3,750 units vested on May 18, 2026, one day before MACROGENICS’ 2026 annual meeting. Upon vesting, they were converted into 3,750 shares of common stock, increasing her direct share ownership.

How many MACROGENICS (MGNX) common shares does Karen Ferrante hold after these transactions?

Following the reported transactions, Karen Ferrante directly holds 14,750 shares of MACROGENICS common stock. This figure reflects the conversion of 3,750 vested RSUs into common shares on May 18, 2026, as shown in the Form 4 filing.

What are the key terms of Karen Ferrante’s new MACROGENICS (MGNX) stock options?

The stock options cover 22,000 shares of MACROGENICS common stock at a $4.52 exercise price and expire on May 19, 2036. They vest in monthly, cumulative 1/12th increments starting one month after the May 19, 2026 grant date.

How do the MACROGENICS (MGNX) RSUs reported for Karen Ferrante function?

Each RSU represents a contingent right to receive one share of MACROGENICS common stock. RSUs vest on specified dates, such as one year after grant, and upon vesting they convert into common shares that increase the holder’s direct share ownership.